139 related articles for article (PubMed ID: 20635890)
1. Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia.
van den Ancker W; van Luijn MM; Westers TM; Bontkes HJ; Ruben JM; de Gruijl TD; Ossenkoppele GJ; van de Loosdrecht AA
Immunotherapy; 2010 Jan; 2(1):69-83. PubMed ID: 20635890
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cell-based immunotherapy in myeloid leukaemia: translating fundamental mechanisms into clinical applications.
van de Loosdrecht AA; van den Ancker W; Houtenbos I; Ossenkoppele GJ; Westers TM
Handb Exp Pharmacol; 2009; (188):319-48. PubMed ID: 19031033
[TBL] [Abstract][Full Text] [Related]
3. Impaired antigen presentation in neoplasia: basic mechanisms and implications for acute myeloid leukemia.
van Luijn MM; van den Ancker W; Chamuleau ME; Ossenkoppele GJ; van Ham SM; van de Loosdrecht AA
Immunotherapy; 2010 Jan; 2(1):85-97. PubMed ID: 20635891
[TBL] [Abstract][Full Text] [Related]
4. Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin.
Spisek R; Chevallier P; Morineau N; Milpied N; Avet-Loiseau H; Harousseau JL; Meflah K; Gregoire M
Cancer Res; 2002 May; 62(10):2861-8. PubMed ID: 12019165
[TBL] [Abstract][Full Text] [Related]
5. Principles of dendritic cell-based immunotherapy in myeloid leukemia.
Westers TM; Houtenbos I; van de Loosdrecht AA; Ossenkoppele GJ
Immunobiology; 2006; 211(6-8):663-76. PubMed ID: 16920505
[TBL] [Abstract][Full Text] [Related]
6. Presentation of tumor antigens by phagocytic dendritic cell clusters generated from human CD34+ hematopoietic progenitor cells: induction of autologous cytotoxic T lymphocytes against leukemic cells in acute myelogenous leukemia patients.
Fujii S; Fujimoto K; Shimizu K; Ezaki T; Kawano F; Takatsuki K; Kawakita M; Matsuno K
Cancer Res; 1999 May; 59(9):2150-8. PubMed ID: 10232602
[TBL] [Abstract][Full Text] [Related]
7. Reconstitution of CD40 and CD80 in dendritic cells generated from blasts of patients with acute myeloid leukemia.
Li L; Schmitt A; Reinhardt P; Greiner J; Ringhoffer M; Vaida B; Bommer M; Vollmer M; Wiesneth M; Döhner H; Schmitt M
Cancer Immun; 2003 Jul; 3():8. PubMed ID: 12862419
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts.
Li L; Giannopoulos K; Reinhardt P; Tabarkiewicz J; Schmitt A; Greiner J; Rolinski J; Hus I; Dmoszynska A; Wiesneth M; Schmitt M
Int J Oncol; 2006 Apr; 28(4):855-61. PubMed ID: 16525634
[TBL] [Abstract][Full Text] [Related]
9. Chronic myeloid leukemia lysate-loaded dendritic cells induce T-cell responses towards leukemia progenitor cells.
Westers TM; van den Ancker W; Bontkes HJ; Janssen JJ; van de Loosdrecht AA; Ossenkoppele GJ
Immunotherapy; 2011 Apr; 3(4):569-76. PubMed ID: 21463196
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of clinical dendritic cell vaccination in acute myeloid leukemia.
Houtenbos I; Westers TM; Ossenkoppele GJ; van de Loosdrecht AA
Immunobiology; 2006; 211(6-8):677-85. PubMed ID: 16920506
[TBL] [Abstract][Full Text] [Related]
11. Optimization of the concentration of autologous serum for generation of leukemic dendritic cells from acute myeloid leukemic cells for clinical immunotherapy.
Choi BH; Kang HK; Park JS; Kim SK; Pham TN; Zhu XW; Cho D; Nam JH; Chung IJ; Kim YJ; Rhee JH; Kim HJ; Lee JJ
J Clin Apher; 2006 Dec; 21(4):233-40. PubMed ID: 17120232
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells.
Curti A; Pandolfi S; Aluigi M; Isidori A; Alessandrini I; Chiodoni C; Testoni N; Colombo MP; Baccarani M; Lemoli RM
Exp Hematol; 2005 Dec; 33(12):1521-30. PubMed ID: 16338495
[TBL] [Abstract][Full Text] [Related]
14. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H
J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
[TBL] [Abstract][Full Text] [Related]
15. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens.
Li L; Reinhardt P; Schmitt A; Barth TF; Greiner J; Ringhoffer M; Döhner H; Wiesneth M; Schmitt M
Cancer Immunol Immunother; 2005 Jul; 54(7):685-93. PubMed ID: 15627212
[TBL] [Abstract][Full Text] [Related]
17. Optimizing the exogenous antigen loading of monocyte-derived dendritic cells.
Dieckmann D; Schultz ES; Ring B; Chames P; Held G; Hoogenboom HR; Schuler G
Int Immunol; 2005 May; 17(5):621-35. PubMed ID: 15824067
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation.
Lee JJ; Kook H; Park MS; Nam JH; Choi BH; Song WH; Park KS; Lee IK; Chung IJ; Hwang TJ; Kim HJ
J Clin Apher; 2004; 19(2):66-70. PubMed ID: 15274198
[TBL] [Abstract][Full Text] [Related]
19. Preparation and identification of a novel immunomodulator composed of muramyl dipeptide and anti-CD10 monoclonal antibody for treatment of minimal residual disease in acute leukemia children.
Wang LZ; Sun LR; Zhao YX; Wang LL
Int Immunopharmacol; 2011 Sep; 11(9):1211-9. PubMed ID: 21492747
[TBL] [Abstract][Full Text] [Related]
20. Cross-priming of CD8(+) T cells in vivo by dendritic cells pulsed with autologous apoptotic leukemic cells in immunotherapy for elderly patients with acute myeloid leukemia.
Kitawaki T; Kadowaki N; Fukunaga K; Kasai Y; Maekawa T; Ohmori K; Itoh T; Shimizu A; Kuzushima K; Kondo T; Ishikawa T; Uchiyama T
Exp Hematol; 2011 Apr; 39(4):424-433.e2. PubMed ID: 21216276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
